Lehrstuhl für Innere Medizin V

Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd (2022) Habenicht K, Bootz A, Schäfer S, Vasova I, Fante M, Schneider A, Rehli M, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1a-Mediated Apoptosis Following Unfolded Protein Response (2022) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Conference contribution Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity (2022) Pelzl R, Kübel S, Klein P, Gsottberger F, Wendland K, Petkovic S, Brueckl V, et al. Conference contribution Expression of disialoganglioside GD2 in breast cancer subtypes (2022) Gaß P, Kailayangiri S, Hübner H, Rübner M, Hartmann A, Häberle L, Völkl S, et al. Conference contribution Role of CAR T Cell Metabolism for Therapeutic Efficacy (2022) Rial Saborido J, Völkl S, Aigner M, Mackensen A, Mougiakakos D Journal article, Review article Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium (2022) Lüke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spörl S, et al. Journal article HLA-DO: a possible switch between GvHD and GvL effect (2022) Zeun J, Neubeck S, Lang V, Flamann C, Nagel L, Kunert T, Vogler T, et al. Conference contribution CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus (2022) Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al. Conference contribution BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, et al. Conference contribution